Outlook Therapeutics (Outlook Therapeutics) LT-Debt-to-Total-Asset : 0.00 (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Outlook Therapeutics LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Outlook Therapeutics's long-term debt to total assests ratio for the quarter that ended in Dec. 2023 was 0.00.

Outlook Therapeutics's long-term debt to total assets ratio declined from Dec. 2022 (0.51) to Dec. 2023 (0.00). It may suggest that Outlook Therapeutics is progressively becoming less dependent on debt to grow their business.

Outlook Therapeutics LT-Debt-to-Total-Asset Historical Data

The historical data trend for Outlook Therapeutics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Outlook Therapeutics LT-Debt-to-Total-Asset Chart

Outlook Therapeutics Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.20

0.05

0.48

Outlook Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.51	-	-	-	-

Outlook Therapeutics LT-Debt-to-Total-Asset Calculation

Outlook Therapeutics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Sep. 2023 is calculated as

LT Debt to Total Assets (A: Sep. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Sep. 2023 )	/	Total Assets (A: Sep. 2023 )
	=	0	/	32.301
	=

Outlook Therapeutics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (Q: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2023 )	/	Total Assets (Q: Dec. 2023 )
	=	0	/	21.685
	=

Outlook Therapeutics (NAS:OTLK) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Outlook Therapeutics LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Outlook Therapeutics's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Outlook Therapeutics (Outlook Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Outlook Therapeutics Inc (NAS:OTLK) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

41ON:Germany 41ON:Germany

Address

485 Route 1 South Building F, Suite 320, Iselin, NJ, USA, 08852

Website

https://www.outlooktherapeutics.com

Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications.

Executives

Terry Dagnon	officer: Chief Operating Officer	C/O ONCOBIOLOGICS, INC., 7 CLARKE DRIVE, CRANBURY NJ 08512
Jeff Evanson	officer: Chief Commercial Officer	C/O ONCOBIOLOGICS, INC., 7 CLARKE DRIVE, CRANBURY NJ 08512
Yezan Munther Haddadin	director	ZAHRAN STREET, 7TH CIRCLE ZAHRAN PLAZA, 4TH FLOOR, PO BOX 142904, AMMAN M2 11844
Faisal Ghiath Sukhtian	director	7TH CIRCLE, ZAHRAN ST., ZAHRAN PLAZA BLDG,4TH FLR, PO BOX 142909, AMMAN M2 11844
Kurt J Hilzinger	director	1300 MORRIS DRIVE, SUITE 100, CHESTERBROOK PA 19087
Julia A Haller	director	C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Trenary C Russell Iii	director, officer: CEO and President	1700 E ST ANDREW PLACE, SANTA ANA CA 92705
Ghiath M. Sukhtian	director, 10 percent owner	7TH CIRCLE, ZAHRAN ST., ZAHRAN PLAZA BUILDING, 4TH FLOOR, AMMAN M2 11844
Lawrence A Kenyon	officer: CFO and Secretary	C/O OUTLOOK THERAPEUTICS, INC., 7 CLARKE DRIVE, CRANBURY NJ 08512
Syntone Ventures Llc	10 percent owner	1517 CHAMPLAIN CREST WAY, CARY NC 27513
Randy H Thurman	director	222 MERCHANDISE MART PLAZA, SUITE 2024, CHICAGO IL 60654
Andong Huang	director	C/O OUTLOOK THERAPEUTICS, INC., 4260 US ROUTE 1, MONMOUTH JUNCTION NJ 08852
Gerd Auffarth	director	C/O PRESBIA PLC, 120/121 BAGGOT STREET LOWER, DUBLIN 2 L2 00000
Julian S Gangolli	director	4955 BASELINE AVENUE, SANTA YNEZ CA 93460
Gms Ventures & Investments	director	C/O INTERTRUST CORP. SVCS. (CAYMAN) LTD., 190 ELGIN AVENUE, GEORGE TOWN E9 KYI-9007